Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis

Thrombosis and Haemostasis

Volumn 76, Issue 4, 1996, Pages 615-620

  Kaiser, Brigitte ^a   Fareed, Jawed ^b  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING INHIBITOR; PROTHROMBIN; RECOMBINANT PROTEIN; THROMBIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BALLOON CATHETER; BLOOD CLOT LYSIS; CONTROLLED STUDY; FEMALE; FEMORAL ARTERY; INTRAVENOUS DRUG ADMINISTRATION; JUGULAR VEIN; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RABBIT; THROMBIN TIME; THROMBOGENESIS; VEIN BLOOD FLOW; VEIN OCCLUSION; VEIN THROMBOSIS;

EID: 0029833603     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650631     Document Type: Article

References (31)

1. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance and regulation. Biochemistry 1991; 30: 10363-70.
2. Petersen LC, Valentin S, Hedner U. Regulation of the extrinsic pathway system in health and disease: the role of factor VIIa and tissue factor pathway inhibitor. Thromb Res 1995; 79: 1-47.
3. Rapaport SI, Rao LVM. The tissue factor pathway: how it has become a prima ballerina. Thromb Haemost 1995; 74: 7-17.
4. Nemerson Y. The tissue factor pathway of blood coagulation. Semin Hematol 1992; 29; 170-6.
5. Carson SD, Brozna JP. The role of tissue factor in the production of thrombin. Blood Coag Fibrinol 1993; 4: 281-92.
6. Girard TJ, Warren LA, Novotny WF, Liken KM, Brown SG, Miletich JP, Broze Jr GJ. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 1989; 338: 518-20.
7. Pedersen AH, Nordfang O, Noms F, Wiberg FC, Christensen M, Bach Moellers K, Meidahl-Pedersen J, Beck TC, Norris K, Hedner U, Kisiel W. Recombinant human extrinsic pathway inhibitor: production, isolation, and characterization of its inhibitory activity on tissue factor-initiated coagulation reactions. J Biol Chem 1990; 265: 16786-93.
8. Broze Jr GJ, Girard TJ, Novotny WF. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 1990; 29: 7539-46.
9. Broze Jr GJ. Tissue factor pathway inhibitor. Thromb Haemost 1995; 74: 90-3.
10. Broze Jr GJ. Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coag Fibrinol 1995; suppl 1; 6: S1-13.
11. Sandset PM, Abildgaard U. Extrinsic pathway inhibitor - the key to feedback control of blood coagulation initiated by tissue thromboplastin. Haemostasis 1991; 21: 219-39.
12. Rapaport SI. The extrinsic pathway inhibitor: a regulator of tissue-factor dependent blood coagulation. Thromb Haemost 1991; 66: 6-15.
13. Lindahl AK. Tissue factor pathway inhibitor in health and disease. Trends Cardiovasc Med 1995; 5: 167-71.
14. Lindahl AK, Sandset PM, Abildgaard U. The present status of tissue factor pathway inhibitor. Blood Coag Fibrinol 1992; 3: 439-49.
15. Wada H, Wakita Y, Shiku H. Tissue factor expression in endothelial cells in health and disease. Blood Coag Fibrinol 1995; suppl 1; 6: S26-31.
16. Abildgaard U. Relative roles of tissue factor pathway inhibitor and antithrombin in the control of thrombogenesis. Blood Coag Fibrinol 1995; suppl 1; 6: S45-9.
17. Hoppensteadt DA, Jeske W, Fareed J, Bermes Jr EW. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin. Blood Coag Fibrinol 1995; suppl 1; 6: S57-64.
18. Abildgaard U. Heparin/low molecular weight heparin and tissue factor pathway inhibitor. Haemostasis 1993; suppl 1; 23: 103-6.
19. Hufnagel CA. Deep vein thrombosis: an overview. Angiology 1990; 41: 337-51.
20. Diquelou A, Dupouy D, Gaspin D, Constans J, Sié P, Boneu B, Sakariassen KS, Cadroy Y. Relationship between endothelial tissue factor and thrombogenesis under blood flow conditions. Thromb Haemost 1995; 74: 778-83.
21. Kaiser B, Hoppensteadt DA, Jeske W, Wun TC, Fareed J. Inhibitory effects of TFPI on thrombin and factor Xa generation in vitro - modulatory action of glycosaminoglycans. Thromb Res 1994; 75: 609-16.
22. Kaiser B, Jeske W, Hoppensteadt D, Fareed J. Inhibitory effects of TFPI variants on thrombin and factor Xa generation in fibrinogen-deficient human plasma. Thromb Res 1994; 76: 561-8.
23. 1-161) in experimental venous thrombosis - a comparison with low molecular weight heparin. Thromb Haemost 1994; 71: 214-9.
24. Day KC, Hoffmann LC, Palmier MO, Kretzmer KK, Huang MD, Pyla EY, Spokas E, Broze Jr GJ, Warren TG, Wun T-C. Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue thromboplastin-induced intravascular coagulation in the rabbit. Blood 1990; 76: 1538-45.
25. Bregengard C, Nordfang O, Wildgoose P, Svendsen O, Hedner U, Diness V. The effect of two-domain tissue factor pathway inhibitor on endotoxin-induced disseminated intravascular coagulation in rabbits. Blood Coag Fibrinol 1993; 4: 699-706.
26. Carr C, Bild GS, Chang ACK, Peer GT, Palmier MO, Frazier RB, Gustafson ME, Wun T-C, Creasey AA, Hinshaw LB, Taylor Jr FB, Galluppi GR. Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock. Circulatory Shock 1995; 44: 126-37.
27. Abendschein DR, Meng YY, Torr-Brown S, Sobel BE. Maintenance of coronary patency after fibrinolysis with tissue factor pathway inhibitor. Circulation 1995; 92: 944-9.
28. Haskel EJ, Ton SR, Day KC, Palmier MO, Wun T-C, Sobel BE, Abendschein DR. Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor. Circulation 1991; 84: 821-7.
29. Lindahl AK, Sandset PM, Thune-Wiiger M, Nordfang O, Sakariassen KS. Tissue factor pathway inhibitor prevents thrombus formation on procoagulant subendothelial matrix. Blood Coag Fibrinol 1994; 5: 755-60.
30. Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP. Importance of factor Xa in determining ihe procoagulant activity of whole-blood clots. J Clin Invest 1993; 91: 1877-83.
31. Prager NA, Abendschein DR, McKenzie CR, Eisenberg PR. Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots. Circulation 1995; 92: 962-7.